8-K: NeoGenomics Q1 2026 Revenue Hits Record $187M

NeoGenomics reported record first-quarter revenue of $187 million, an 11% year-over-year increase, and raised its full-year 2026 revenue guidance.

Summary

• Total revenue reached a record $187 million for Q1 2026, up 11% year-over-year.
• Clinical revenue grew 14%, with NGS (Next-Generation Sequencing) revenue increasing by 26%.
• Net loss narrowed by 34% to $17 million compared to $26 million in Q1 2025.
• Adjusted EBITDA rose 27% to $9 million.
• Average revenue per clinical test increased 8% to $495.
• Full-year 2026 revenue guidance was raised to a range of $797 million to $803 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, characterized by double-digit revenue growth, improved profitability, and successful execution of a high-value product launch strategy.

Positives

• Record quarterly revenue of $187 million.
• Strong 26% growth in NGS testing revenue.
• Significant improvement in profitability with a 34% reduction in net loss.
• Adjusted EBITDA growth of 27% year-over-year.
• Successful launch of the RaDaR ST MRD assay, targeting a $20 billion addressable market.
• Favorable MolDX coverage decision for the PanTracer LBx test.

Negatives

• Reported a GAAP net loss of $17.1 million for the quarter.
• Operating expenses remain high at $99.1 million, despite a slight 2% reduction.
• Cash and cash equivalents decreased from $159.6 million at year-end 2025 to $146.1 million as of March 31, 2026.

Risks

• Potential impact of evolving regulatory requirements related to laboratory-developed tests (LDTs).
• Uncertainty regarding reimbursement changes by government and commercial payors.
• Risks associated with integrating acquisitions and managing supply chain costs.
• Market penetration challenges for the newly launched RaDaR ST assay.
• Dependence on continued growth in clinical test volumes to achieve long-term revenue targets.

Future Outlook

The company raised its full-year 2026 revenue guidance to a range of $797 million to $803 million, reflecting confidence in its core clinical business and new product launches.

Management Comments

• The first quarter of 2026 was a truly transformational one for NeoGenomics.
• The full clinical launch of our RaDaR ST MRD assay represents an important advancement in residual disease monitoring.
• These important additions further differentiate our portfolio, advancing our objective to deliver long-term predictable revenue growth.

Industry Context

StockSavvy.ai notes that NeoGenomics is successfully pivoting toward high-growth molecular diagnostics like MRD and CGP, aligning with the broader industry trend of shifting from traditional pathology to precision oncology testing.

Comparison to Industry Standards

• Revenue growth of 11% is competitive with peers in the specialized diagnostics space.
• The focus on NGS and MRD testing positions the company alongside major players like Exact Sciences and Guardant Health in the liquid biopsy and genomic profiling markets.
• The company's ability to improve gross margins to 46% (adjusted) demonstrates operational efficiency comparable to established diagnostic laboratories.

Stakeholder Impact

• Shareholders: Positive impact due to revenue growth and improved guidance.
• Customers: Benefit from expanded diagnostic menu and improved testing workflows.
• Employees: Continued focus on operational efficiency and product innovation.

Next Steps

• Execution of the full clinical launch of the RaDaR ST MRD assay.
• Continued integration of PanTracer Pro into clinical workflows.
• Monitoring of reimbursement trends for PanTracer LBx.

Key Dates

Recommendation

The company is demonstrating clear operational leverage, strong top-line growth, and a successful transition into high-margin molecular diagnostic products, justifying a positive outlook.

Keywords

NeoGenomics, oncology diagnostics, precision medicine, NGS, RaDaR, cancer genetics, molecular testing, NEO